Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 6/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | FNTA | P49354 | 1/20 | 0.38 |
| ▸ | FNTB | P49356 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 3/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7101820 | 0.88 | PTGS1 (0.44) | MAPTTDP1LMNASMN1; SMN2TSHR | |
| SCHEMBL6166501 | 0.86 | MAPT (0.47) | MAPTTDP1LMNASMN1; SMN2TSHR | |
| SCHEMBL6163869 | 0.84 | POLB (0.45) | MAPTTDP1LMNASMN1; SMN2TSHR | |
| SCHEMBL6170882 | 0.84 | MAPT (0.45) | MAPTTDP1LMNASMN1; SMN2TSHR | |
| SCHEMBL6164731 | 0.83 | TSHR (0.45) | MAPTTDP1LMNASMN1; SMN2TSHR | |
| SCHEMBL6163697 | 0.83 | TSHR (0.45) | MAPTTDP1LMNASMN1; SMN2TSHR | |
| SCHEMBL7105719 | 0.81 | POLB (0.47) | SMN1; SMN2TSHRPTGS1PTGS2ELANE | |
| SCHEMBL6163207 | 0.79 | TSHR (0.46) | LMNATSHRPTGS1PTGS2ELANE | |
| SCHEMBL7108857 | 0.79 | POLB (0.46) | SMN1; SMN2TSHRPTGS1PTGS2ELANE | |
| SCHEMBL7106357 | 0.78 | SMN1; SMN2 (0.41) | MAPTTDP1LMNASMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030065176-A1 | Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof | LG CHEM INVESTMENT LTD. (KR) | 2003-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065176-A1 | Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof | F2, F12, TFPI | PDE5A 388/4885MAPT 4356/4885TDP1 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.